Propionic Acidemia Clinical Trial
Official title:
A Non-Interventional Post-Authorization Safety Study (PASS) of Carbaglu® for the Treatment of Hyperammonemia Due to Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA) in Adult and Pediatric Patient Populations
To obtain short-term and long-term clinical safety information, in pediatric and adult patients with PA and MMA treated with Carbaglu®.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | June 30, 2032 |
Est. primary completion date | June 30, 2032 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: 1. Provision of signed and dated informed consent/assent form 2. Prescribed and treated with Carbaglu® 3. Have an established diagnosis of PA or MMA defined as follows: - Diagnosed with PA by semi quantitative urine organic acid analysis, defined as presence of elevated methylcitric acid and normal methylmalonic acid levels and no evidence of biotin related disorders in the organic acid analysis; OR - Diagnosed with MMA by semi quantitative urine organic acid analysis, defined as elevation of methylmalonic acid and no evidence of vitamin B12 dependent disorder on plasma amino acid analysis (vitamin B12 dependency is defined by documented vitamin B12 responsiveness). AND/OR - Confirmation by molecular genetic testing Exclusion Criteria: - None |
Country | Name | City | State |
---|---|---|---|
United States | Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago | Illinois |
United States | Riley Children's Hospital | Indianapolis | Indiana |
United States | Icahn School of Medicine at Mt. Sinai | New York | New York |
United States | University of South Florida | Tampa | Florida |
United States | Children's National Hospital | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Recordati Rare Diseases | Target PharmaSolutions, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effects of Carbaglu® on plasma ammonia levels | Multiple plasma ammonia levels will be collected only during treatment with Carbaglu® according to prescribing information and routine medical practice in terms of visit frequency. | Patients treated with Carbaglu® will be managed chronically (out-patient) or acutely (hospital in-patient). In both cases, data will be collected for approximately 1 year following discontinuation of Carbaglu treatment. | |
Primary | Adverse Event frequency and severity | Any Carbaglu® related adverse events will be be collected and reported | Patients treated with Carbaglu® will be managed chronically (out-patient) or acutely (hospital in-patient). In both cases, data will be collected for approximately 1 year following discontinuation of Carbaglu treatment. | |
Secondary | Fetal Outcomes and Pregnancy Outcomes | Pregnancy risks including maternal complications, adverse effects on the developing fetus and neonate, and adverse effects on the infant (through the first year of life). | Collection of pregnancy information for patients who becomes pregnant while participating in the trial or at time of enrollment. Pregnancy reports and reports involving neonates and infants up to 1 year of age must be reported to RRD Pharmacovigilance. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05842837 -
A Non-Interventional Post-Authorization Study of Carbaglu for the Treatment of Hyperammonemia Due to MMA and PA
|
||
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Recruiting |
NCT05130437 -
A Long-Term Extension Study to Evaluate the Safety and Clinical Activity of mRNA-3927
|
Phase 1/Phase 2 | |
Recruiting |
NCT02890342 -
Natural History, Physiology, Microbiome and Biochemistry Studies of Propionic Acidemia
|
||
Completed |
NCT02426775 -
Carglumic Acid in Methylmalonic Acidemia and Propionic Acidemia
|
Phase 3 | |
Terminated |
NCT04836494 -
A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic Acidemia
|
Phase 1 | |
Completed |
NCT03484767 -
"The MaP Study": Mapping the Patient Journey in MMA and PA
|
||
Terminated |
NCT04732429 -
Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia
|
Phase 2 | |
Recruiting |
NCT05769621 -
A Retrospective Study to Characterize Participants With Propionic Acidemia
|
||
Completed |
NCT00645879 -
Anaplerotic Therapy in Propionic Acidemia
|
Phase 1 | |
Recruiting |
NCT04176523 -
Understanding the Long-Term Management of Organic Acidemia Patients With CARBAGLU®: A Mixed Methods Approach
|
||
Withdrawn |
NCT01341379 -
Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate
|
Phase 2 | |
Terminated |
NCT05438485 -
Natural History Study of Patients With Methylmalonic Acidemia and Propionic Acidemia
|
||
Completed |
NCT03159026 -
Review of Charts From Amish/Mennonite Variant PA Patients
|
||
Recruiting |
NCT04159103 -
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
|
Phase 1/Phase 2 |